Abstract
Positron emission tomography (PET) is a very sensitive molecular imaging technique that when employed with an appropriate radioligand has the ability to quantititate physiological processes in a non-invasive manner. Since the imaging technique detects all radioactive emissions in the field of view, the presence and biological activity of radiolabeled metabolites must be determined for each radioligand in order to validate the utility of the radiotracer for measuring the desired physiological process. Thus, the identification of metabolic profiles of radiolabeled compounds is an important aspect of design, development, and validation of new radiopharmaceuticals and their applications in drug development and molecular imaging. Metabolite identification for different chemical classes of radiopharmaceuticals allows rational design to minimize the formation and accumulation of metabolites in the target tissue, either through enhanced excretion or minimized metabolism. This review will discuss methods for identifying and quantitating metabolites during the pre-clinical development of radiopharmaceuticals with special emphasis on the application of LC/MS.
Keywords: Positron emission tomography (PET), Radiopharmaceutical, LC/MS/MS, Metabolite
Current Drug Metabolism
Title: Applications of LC-MS in PET Radioligand Development and Metabolic Elucidation
Volume: 11 Issue: 6
Author(s): Ying Ma, Dale O. Kiesewetter, Lixin Lang, Dongyu Gu and Xiaoyuan Chen
Affiliation:
Keywords: Positron emission tomography (PET), Radiopharmaceutical, LC/MS/MS, Metabolite
Abstract: Positron emission tomography (PET) is a very sensitive molecular imaging technique that when employed with an appropriate radioligand has the ability to quantititate physiological processes in a non-invasive manner. Since the imaging technique detects all radioactive emissions in the field of view, the presence and biological activity of radiolabeled metabolites must be determined for each radioligand in order to validate the utility of the radiotracer for measuring the desired physiological process. Thus, the identification of metabolic profiles of radiolabeled compounds is an important aspect of design, development, and validation of new radiopharmaceuticals and their applications in drug development and molecular imaging. Metabolite identification for different chemical classes of radiopharmaceuticals allows rational design to minimize the formation and accumulation of metabolites in the target tissue, either through enhanced excretion or minimized metabolism. This review will discuss methods for identifying and quantitating metabolites during the pre-clinical development of radiopharmaceuticals with special emphasis on the application of LC/MS.
Export Options
About this article
Cite this article as:
Ma Ying, O. Kiesewetter Dale, Lang Lixin, Gu Dongyu and Chen Xiaoyuan, Applications of LC-MS in PET Radioligand Development and Metabolic Elucidation, Current Drug Metabolism 2010; 11 (6) . https://dx.doi.org/10.2174/138920010791636167
DOI https://dx.doi.org/10.2174/138920010791636167 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Can Probiotics Supplementation Improve Glycemic and Renal Status in
Diabetic Nephropathy? A Systematic Review and Meta-Analysis of Clinical
Trials
Endocrine, Metabolic & Immune Disorders - Drug Targets Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Non-Enzymatic Protein Acetylation by 7-Acetoxy-4-Methylcoumarin: Implications in Protein Biochemistry
Protein & Peptide Letters Anaesthetic Drugs: Linking Molecular Actions to Clinical Effects
Current Pharmaceutical Design Synthesis of 2`-hydroxy-4`-isoprenyloxychalcone Derivatives with Potential Antidepressant-like Activity
Medicinal Chemistry Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Current Vascular Pharmacology Synthesis of Hitherto Unknown 4,4-Bis(methylthio)but-3-en-2-one-1,1,1,3- d4 and Its Application as 1,3-Dielectrophilic Building Block for the Synthesis of Deuterated Heterocycles and Aromatics
Letters in Organic Chemistry 2D Depiction of Biological Interactions and Its Applications in Drug Design
Current Medical Imaging Structural Basis of Infectious and Non-Infectious Amyloids
Current Alzheimer Research Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Targeting Proliferating Cell Nuclear Antigen (PCNA) as an Effective Strategy to Inhibit Tumor Cell Proliferation
Current Cancer Drug Targets Roles of Biogenic Amines in Intestinal Signaling
Current Protein & Peptide Science Evaluation of the Pharmacological Descriptors Related to the Induction of Antidepressant Activity and its Prediction by QSAR/QRAR Methods
Mini-Reviews in Medicinal Chemistry Arboviral Encephalitis and RNAi Treatment
Central Nervous System Agents in Medicinal Chemistry Hepatic Effects of Duloxetine – III: Analysis of Hepatic Events Using External Data Sources
Current Drug Safety Drugs from the Sea: Conopeptides as Potential Therapeutics
Current Medicinal Chemistry Recent Progress in the Discovery of Novel Glucocorticoid Receptor Modulators
Current Topics in Medicinal Chemistry